Traf3ip3: A Potential Drug Target for Various Diseases (G80342)

Target Name: TRAF3IP3

NCBI ID: G80342

TRAF3IP3

Traf3ip3: A Potential Drug Target for Various Diseases

Traf3ip3 (T3JAM-HUMAN), a protein found in human tissues, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

The protein Traf3ip3 is a member of the tyrosine kinase family, which is a group of transmembrane proteins that play a crucial role in cell signaling. Traf3ip3 is characterized by its unique molecular structure, which consists of a long N-terminus, a single transmembrane segment, and a C-terminus that is rich in amino acids, including glutamic acid, which is known for its ability to interact with other proteins.

One of the key features of Traf3ip3 is its ability to interact with several different proteins, including casein kinase (CK) 3, which is a protein that is involved in many cellular processes, including cell signaling, DNA replication, and protein synthesis. CK3 is a non-catalytic protein that can interact with various transcription factors, including T-cell factor (TGF-1), to regulate cellular processes.

Traf3ip3 has been shown to play a role in several cellular processes, including cell signaling, cell division, and protein synthesis. It has been shown to interact with casein kinase (CK) 3, which is a protein that is involved in many cellular processes, including cell signaling, DNA replication, and protein synthesis. CK3 is a non-catalytic protein that can interact with various transcription factors, including T-cell factor (TGF-1), to regulate cellular processes.

Another potential drug target for Traf3ip3 is its role in the development of neurodegenerative disorders. Neurodegenerative disorders are a group of diseases that are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. These disorders include Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Research has shown that Traf3ip3 is involved in the development and progression of neurodegenerative disorders. Studies have shown that Traf3ip3 is expressed in the brains of individuals with Alzheimer's disease and Parkinson's disease, and that its levels are reduced in individuals with these disorders. Additionally, Traf3ip3 has been shown to interact with several neurotransmitters, including dopamine and beta-amyloid, which are involved in the development and progression of neurodegenerative disorders.

Traf3ip3 has also been shown to be involved in the development and progression of autoimmune diseases. Autoimmune diseases are a group of diseases in which the immune system attacks the body's own tissues and causes inflammation. These diseases include rheumatoid arthritis, lupus, and multiple sclerosis.

Research has shown that Traf3ip3 is involved in the development and progression of autoimmune diseases. Studies have shown that Traf3ip3 is expressed in the tissues of individuals with rheumatoid arthritis and lupus, and that its levels are increased in individuals with these disorders. Additionally, Traf3ip3 has been shown to interact with several immune system proteins, including T-cell receptor (TCR) and B-cell receptor (BCR), which are involved in the development and progression of autoimmune diseases.

In conclusion, Traf3ip3 is a protein that has the potential to be a drug target or biomarker for a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand the role of Traf3ip3 in these diseases and to develop new treatments.

Protein Name: TRAF3 Interacting Protein 3

Functions: Adapter protein that plays essential roles in both innate and adaptive immunity. Plays a crucial role in the regulation of thymocyte development (PubMed:26195727). Mechanistically, mediates TCR-stimulated activation through recruiting MAP2K1/MEK1 to the Golgi and, thereby, facilitating the interaction of MAP2K1/MEK1 with its activator BRAF (PubMed:26195727). Also plays an essential role in regulatory T-cell stability and function by recruiting the serine-threonine phosphatase catalytic subunit (PPP2CA) to the lysosome, thereby facilitating the interaction of PP2Ac with the mTORC1 component RPTOR and restricting glycolytic metabolism (PubMed:30115741). Positively regulates TLR4 signaling activity in macrophage-mediated inflammation by acting as a molecular clamp to facilitate LPS-induced translocation of TLR4 to lipid rafts (PubMed:30573680). In response to viral infection, facilitates the recruitment of TRAF3 to MAVS within mitochondria leading to IRF3 activation and interferon production (PubMed:31390091). However, participates in the maintenance of immune homeostasis and the prevention of overzealous innate immunity by promoting 'Lys-48'-dependent ubiquitination of TBK1 (PubMed:32366851)

The "TRAF3IP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAF3IP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets